Spots Global Cancer Trial Database for neoadjuvant
Every month we try and update this database with for neoadjuvant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | NCT02432365 | Cervical Cancer | paclitaxel cisplatin Radical hystere... | 35 Years - 70 Years | Chang Gung Memorial Hospital | |
| MRI Guided SIB Radiotherapy in Neoadjuvant Therapy for Advanced Rectal Cancer | NCT06246344 | Rectal Cancer | MRI Guided Simu... | 18 Years - 75 Years | Shandong Cancer Hospital and Institute | |
| Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma | NCT01382030 | Soft Tissue Sar... | EIA chemotherap... | 18 Years - 65 Years | Heidelberg University | |
| Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | NCT05803915 | Oral Squamous C... | Toripalimab | 18 Years - | Peking Union Medical College Hospital | |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | NCT05563766 | Esophageal Aden... Esophageal Squa... Gastroesophagea... | Itraconazole | 18 Years - | VA Office of Research and Development | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer | NCT02001506 | Breast Cancer | FEC3-D3 | 20 Years - | Asan Medical Center | |
| Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer | NCT03565029 | Colo-rectal Can... | XELOX Radiotherapy | 18 Years - | Niguarda Hospital | |
| Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) | NCT02844075 | Esophageal Squa... | MK-3475(pembrol... | 20 Years - | Yonsei University | |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | NCT00553358 | Neoplasms, Brea... | Lapatinib Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma | NCT04776525 | Soft Tissue Sar... | Ifosfamide Doxorubicin | 18 Years - | Oslo University Hospital | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | NCT05833672 | Colon Cancer Immunotherapy | Terelizumab CapeOx | 18 Years - 80 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer | NCT06144944 | Breast Cancer I... Hormone-recepto... HER2 Low Breast... Early-stage Bre... | Pyrotinib, epir... Placebo, epirub... | 17 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer | NCT06204094 | Locally Advance... | node-sparing sh... Sintilimab Capecitabine Oxaliplatin TME surgery watch and wait | 18 Years - 75 Years | Jinhua Central Hospital | |
| Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC | NCT04543110 | Bladder Cancer | Durvalumab Immune Modulati... | 18 Years - | Ottawa Hospital Research Institute | |
| HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy | NCT02061423 | Breast Cancer | HER-2 pulsed De... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | NCT01650428 | Rectal Cancer | Bevacizumab Irinotecan Oxaliplatin 5-Fluorouracil | 18 Years - 75 Years | University College, London | |
| Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer | NCT00828672 | Locally Advance... | Oxaliplatin Bevacizumab Capecitabine radiotherapy | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma | NCT05185531 | Hepatocellular ... | PD-1 plus stere... | 18 Years - 80 Years | Shandong Cancer Hospital and Institute | |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | NCT01008150 | Breast Cancer | Paclitaxel Trastuzumab Neratinib Doxorubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | NCT01660711 | Pancreatic Aden... | 5 Fluorouracil Leucovorin Irinotecan Oxaliplatin | 18 Years - | NorthShore University HealthSystem | |
| Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | NCT00242918 | Prostate Cancer | docetaxel ZD1839 | 18 Years - | Benaroya Research Institute | |
| A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer | NCT05104788 | Non-Small Cell ... | Icotinib Cisplatin Carboplatin Pemetrexed | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | NCT03294304 | Muscle Invasive... | Nivolumab Cisplatin Gemcitabine | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | NCT04612894 | Thyroid Cancer | Camrelizumab an... surgery core needle bio... | 14 Years - | Fudan University | |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | NCT04310397 | Pathologic Stag... Pathologic Stag... Pathologic Stag... | Dabrafenib Spartalizumab Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer | NCT02619669 | Breast Cancer | TAK-228 Letrozole | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . | NCT03275506 | Ovarian Cancer ... | Pembrolizumab I... Chemotherapy - ... | 18 Years - 75 Years | ARCAGY/ GINECO GROUP | |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | NCT01996267 | Breast Cancer HER2 Positive | PTC+Pertuzumab FEC-T+Pertuzuma... | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant Atezolizumab in Cutaneous Melanoma | NCT04020809 | Cutaneous Melan... | Atezolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer | NCT03712774 | Quality of Life Chemoradiation Esophageal Canc... | EORTC QLQ C30 EORTC QLQ OES-1... EORTC OG-25 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | NCT04676997 | Triple Negative... | Camrelizumab Nab paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma | NCT05525273 | Craniopharyngio... | Oral dabrafenib... | 18 Years - | Skane University Hospital | |
| Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | NCT05044728 | Non-small Cell ... Esophageal Squa... | Anti-PD-1 antib... Surgical treatm... | 18 Years - 72 Years | Sichuan Cancer Hospital and Research Institute | |
| Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum | NCT00909987 | Rectum Cancer | Capecitabine Oxaliplatin Bevacizumab Radiotherapy Capecitabine du... Total Mesorecta... | 18 Years - | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant | NCT03447132 | Breast Neoplasm... | Fulvestrant 500... Palbociclib 125... Goserelin 3.6 M... Placebos | 18 Years - | International Cancer Research Group, United Arab Emirates | |
| Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer | NCT01203267 | Breast Cancer | Paclitaxel, Car... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer | NCT00924209 | NSCLC Stage IIIA (N2) | Gemcitabine Cisplatin Bevacizumab Surgery Etoposide | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | NCT04995094 | Pathologic Stag... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | NCT03886493 | Prostate Cancer | Dupilumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | NCT00480935 | Renal Cell Carc... | Sunitinib Malat... | 18 Years - | University Health Network, Toronto | |
| Preoperative Chemoradiation for Glioblastoma | NCT02092038 | Glioblastoma | Temozolomide partial brain i... stereotactic bi... craniotomy and ... | 18 Years - 80 Years | Tampa General Hospital | |
| Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer | NCT04296240 | Rectal Cancer | Oxaliplatin and... Total Mesorecta... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer | NCT05522907 | Prostate Cancer | - | First Affiliated Hospital Xi'an Jiaotong University | ||
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer | NCT01815853 | Gastric Cancer | Neoadjuvant Che... Neoadjuvant Che... R0 D2 Gastrecto... Adjuvant Chemot... | 18 Years - 75 Years | Sun Yat-sen University | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | NCT03043729 | Rectal Cancer Rectosigmoid Ca... | Oxaliplatin 5-FU Leucovorin Aflibercept | 18 Years - | AIO-Studien-gGmbH | |
| Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer | NCT00347438 | Breast Cancer | Capecitabine | 18 Years - | University of Chicago | |
| Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery | NCT00251329 | Breast Cancer | neoadjuvant che... | 18 Years - | Cancer Research Network | |
| Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma | NCT01382030 | Soft Tissue Sar... | EIA chemotherap... | 18 Years - 65 Years | Heidelberg University | |
| Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | NCT02324998 | Prostate Cancer | Olaparib Degarelix | 18 Years - 73 Years | Cambridge University Hospitals NHS Foundation Trust | |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | NCT06384820 | Cutaneous Squam... | cemiplimab fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer | NCT00912444 | Breast Cancer | Docetaxel, Anth... Docetaxel, cycl... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | NCT03043729 | Rectal Cancer Rectosigmoid Ca... | Oxaliplatin 5-FU Leucovorin Aflibercept | 18 Years - | AIO-Studien-gGmbH | |
| Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma | NCT05025813 | Cutaneous Squam... Head and Neck C... | Pembrolizumab | 18 Years - | Queensland Health | |
| Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | NCT02305186 | Pancreatic Canc... | Pembrolizumab Neoadjuvant Che... | 18 Years - | University of Virginia | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells | NCT00353483 | Breast Neoplasm... | Peripheral bloo... Breast tissue c... Bone marrow bio... | 18 Years - | Washington University School of Medicine | |
| Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma | NCT05025813 | Cutaneous Squam... Head and Neck C... | Pembrolizumab | 18 Years - | Queensland Health | |
| Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer | NCT01516996 | Oropharyngeal C... Hypopharyngeal ... | docetaxel and c... IMRT Nimotuzumab | 18 Years - 70 Years | The Second People's Hospital of Sichuan | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma | NCT05798793 | Oral Squamous C... | Camrelizumab pl... TP | 18 Years - 70 Years | Hospital of Stomatology, Wuhan University | |
| Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | NCT01622361 | Breast Cancer | Adriamycin+Cycl... GnRHa with Tamo... | 20 Years - | Asan Medical Center | |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | NCT01421472 | ER Positive, He... Triple Negative... | MM-121 Paclitaxel | 18 Years - | Merrimack Pharmaceuticals | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC | NCT05575635 | Rectal Cancer | fruquintinib + ... | 18 Years - 75 Years | Henan Provincial People's Hospital | |
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | NCT00455039 | Breast Cancer | GW572016 | - | University of New Mexico | |
| De-escalating Axillary Surgery in Breast Cancer Patients in Nigeria | NCT06039956 | Breast Cancer Axilla; Breast | Sentinel lymph ... | 18 Years - 70 Years | Nova Scotia Health Authority | |
| NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | NCT05825625 | Non-small Cell ... | Atezolizumab Tiragolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
